[Real-world study of tenofovir amibufenamide in the treatment of patients with hepatitis B cirrhosis].

Abstract

Objective: To evaluate the short-term antiviral efficacy and safety profile of tenofovir amibufenamide (TMF) in patients with hepatitis B cirrhosis. Methods: The biochemical indexes, renal function, and complication status in patients with hepatitis B cirrhosis who were treated with tenofovir amibufenamide (TMF) in Beijing You'an Hospital Affiliated to Capital Medical University from March 2022 to June 2024 were retrospectively analyzed. Results: A total of 98 cases with hepatitis B cirrhosis were included. Among them, 62 and 36 cases with hepatitis B cirrhosis had previously undergone partial resection for hepatocellular carcinoma. 66.7% (62/93) of the treated patients were HBV DNA negative before treatment. The longest follow-up time for medication was 24 months, with an average follow-up of (14.1±4.7) months. There were no statistically significant differences in aspartate aminotransferase (AST), alanine aminotransferase (ALT), and total bilirubin (TBil) levels at 18 months of treatment compared with those before treatment (P>0.05). The ALT return to normal rate was 91.3%. The HBV DNA negativity rate was 90.6% and 93.5% at 18 and 12 months of follow-up, respectively. There were no significant changes in the estimated glomerular filtration rate (eGFR) and low-density lipoprotein cholesterol (LDL-C) compared with those before treatment (P>0.05). 36 cases were still HBV DNA positive (including 31 treated and 5 never treated) before treatment. A total of 29 cases were followed up for 12 months, and 24 cases (82.8%) had HBV DNA negative conversion. Conclusion: TMF antiviral therapies have an HBV DNA negative rate of over 80% at 12 months and can improve the liver function in patients with hepatitis B cirrhosis. However, there were no significant changes in renal function and blood lipids before and after treatment.